Takeda’s Adcetris Earns EC Approval

The European Commission has approved Takeda Pharmaceutical’s Adcetris for treating adults with CD30+ Hodgkin lymphoma who are at a higher risk of relapse or progression following an autologous stem cell transplant.

The decision was based on results from a Phase 3 trial showing a 75 percent improvement in progression-free survival.

The brentuximab-vedotin cocktail is being jointly developed by Seattle Genetics and Takeda. Seattle Genetics currently holds the commercial rights to the candidate in the U.S. and Canada.